Skip to content
BBlueBioNanobiotechnology
Applications

One platform, many barriers to cross

Nanoscale delivery is a general solution to a specific problem: getting an active molecule to the right place intact. Here is where our partners are applying it today.

01 / Oncology

Carriers that switch on inside the tumour

Charge-shifting surfaces stay stealthy at physiological pH and become adhesive in the acidic tumour microenvironment. In orthotopic models this raised intratumoural payload concentration 6.2× versus untargeted carriers while liver accumulation fell by half.

6.2×
Intratumoural payload
-51%
Hepatic accumulation

02 / Immunology & vaccines

Thermostable, self-amplifying formulations

Lyophilisation-compatible lipid shells protect self-amplifying RNA through reconstitution, keeping potency above 90% for 30 days at 4 °C and removing ultra-cold logistics from the distribution model.

30 days
Stability at 4 °C
> 90%
Retained potency

03 / Neurology

Crossing the blood–brain barrier on purpose

Transferrin-receptor shuttles deliver oligonucleotides into cortical and hippocampal tissue at levels conventional carriers do not reach, opening durable knockdown strategies for neurodegenerative targets.

4.8×
CNS exposure
21 days
Knockdown duration

04 / Rare disease

Small cohorts, fast formulation cycles

Automated design-of-experiments compresses formulation screening to weeks, making bespoke carrier development viable for patient populations that traditional programme economics ignore.

6 weeks
Screen to lead
40+
Ratios per cycle

05 / Agricultural biotech

Precision delivery in crop science

Biodegradable nanocarriers deliver RNA-based crop protection directly to plant tissue, cutting active-ingredient load per hectare and reducing run-off into surrounding watersheds.

-38%
Active ingredient
100%
Biodegradable shell

06 / Environmental sensing

Field detection of trace contaminants

The same quantum-dot chemistry behind our clinical assays detects heavy metals and endocrine disruptors in water samples at parts-per-trillion sensitivity, with results in under ten minutes.

ppt
Detection limit
9 min
Time to result
Engagement models

Three ways partners work with us

6 weeks

Feasibility study

A fixed-scope six-week package: receptor mapping, carrier screening and a data-backed go/no-go recommendation.

12–30 months

Co-development

A joint programme through preclinical validation, with shared IP terms and milestone-based governance.

Per programme

Technology licence

Access to BrilliantCore™ formulations and manufacturing know-how for your own internal pipeline.

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programs with pharma, biotech and academic groups — from target selection through GMP supply.